Shopping Cart
- Remove All
Your shopping cart is currently empty
CGP 53353
CGP 53353 (DAPH-7) is a PKC inhibitor with inhibitory effects on PKCβII and PKCβI and can be used to study atherosclerosis.
Catalog No. T22650Cas No. 145915-60-2
Select Batch
Purity:98.11%
Contact us for more batch information
CGP 53353
Catalog No. T22650Alias DAPH-7Cas No. 145915-60-2
CGP 53353 (DAPH-7) is a PKC inhibitor with inhibitory effects on PKCβII and PKCβI and can be used to study atherosclerosis.
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose. | Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 5 mg | $129 | In Stock | |
| 10 mg | $198 | In Stock | |
| 25 mg | $455 | In Stock | |
| 50 mg | $787 | In Stock | |
| 100 mg | $1,280 | In Stock | |
| 1 mL x 10 mM (in DMSO) | $143 | In Stock |
Bulk & Custom
Add to Cart
Questions
View MoreInhibitors Related to "CGP 53353"
α-Vitamin E
Cited
Vitamin E, D-α-Tocopherol, Dexrabeprazole Sodium, Alpha-Tocopherol, 5,7,8-Trimethyltocol, (+)-alpha-Tocopherol
T164859-02-9
α-Vitamin E (Dexrabeprazole Sodium) is a naturally-occurring form of vitamin E, a fat-soluble vitamin with potent antioxidant properties.
- $38
Size
QTY
CitedDarovasertib
LXS196
T56001874276-76-2
Darovasertib (LXS196) is a potent, selective, and orally active protein kinase C (PKC) inhibitor with IC50 values of 1.9 nM for PKCα, 0.4 nM for PKCθ, and 3.1 μM for GSK3β.
- $48
Size
QTY
Staurosporine
Cited
CGP 41251, Antibiotic AM-2282, AM-2282
T668062996-74-1
Staurosporine (AM-2282) is a protein kinase inhibitor with ATP-competitive and non-selective inhibitory activity (IC50=6/15/2/3/3000 nM) against PKC, PKA, c-Fgr, phosphorylase kinase and TAOK2. Staurosporine also induces apoptosis.
- $56
Size
QTY
CitedMitoxantrone dihydrochloride
NSC-301739, mitozantrone dihydrochloride, Mitoxantrone hydrochloride, Mitoxantrone 2HCl
T015870476-82-3
Mitoxantrone dihydrochloride (NSC-301739) is the hydrochloride salt of an anthracenedione antibiotic with antineoplastic activity. It is a type II topoisomerase inhibitor.
- $50
Size
QTY
R59949
Cited
R-59949, R 59949
T26019120166-69-0
R59949 is used as a Diacylglycerol kinase (DGK) inhibitor.
- $39
Size
QTY
CitedN-Desmethyltamoxifen hydrochloride
T1214815917-65-4
N-Desmethyltamoxifen hydrochloride is the primary metabolite of tamoxifen in humans.
- $35
Size
QTY
Ellagic acid Cited
Gallogen, Elagostasine
T0465476-66-4
Ellagic acid (Gallogen), a thickened tetracyclic natural product, is a potent CK2 inhibitor (IC50=40 nM; Ki=20 nM) with ATP-competitive properties. Ellagic acid is an antioxidant and also possesses antiproliferative activity.
- $44
Size
QTY
CitedFasudil hydrochloride Cited
HA-1077 hydrochloride, HA-1077, Fasudil HCl, Fasudil (HA-1077) HCl, AT-877
T3060105628-07-7
Fasudil hydrochloride (HA-1077) is a potent inhibitor of ROCK1, PKA, PKC, and MLCK with Ki of 0.33 μM, 1.0 μM, 9.3 μM and 55 μM, respectively.
- $35
Size
QTY
CitedMethyl-Hesperidin
T022811013-97-1
Methyl Hesperidin, a flavanone glycoside (flavonoid) (C28H34O15), is abundant in citrus fruits. Its aglycone form is called hesperetin.
- $50
Size
QTY
DCPLA-ME
Methyl 8-[2-[(2-pentylcyclopropyl)methyl]cyclopropyl]octanoate, Methyl 8-(2-((2-pentylcyclopropyl)methyl)cyclopropyl)octanoate, DCPLA methyl ester, 2-[(2-Pentylcyclopropyl)methyl]cyclopropaneoctanoic acid methyl ester
T1098056687-67-3In house
DCPLA-ME (2-[(2-Pentylcyclopropyl)methyl]cyclopropaneoctanoic acid methyl ester) is the methyl ester form of DCPLA and can be used to treat neurodegenerative diseases. It is an effective PKCε activator.
- $79
Size
QTY
Myricitrin Cited
Myricitrine, Myricetrin
T275717912-87-7
Myricitrin (Myricitrine), a flavonoid compound isolated from the root bark of Myrica cerifera, exerts antinociceptive effects.
- $50
Size
QTY
CitedProduct Introduction
Bioactivity
Chemical Properties
| Description | CGP 53353 (DAPH-7) is a PKC inhibitor with inhibitory effects on PKCβII and PKCβI and can be used to study atherosclerosis. |
| Targets&IC50 | PKCβI:3.8 mM, PKCβII:0.41 mM |
| In vitro | In A10 cells, CGP-53353 (DAPH-7) inhibits glucose-induced cell proliferation when administered at 1 μM for 48-96 hours[1]. At a concentration of 1 μM for the initial 0-48 hours, CGP-53353 inhibits the glucose-induced increase and acceleration of DNA synthesis in A10 cells. It also blocks the glucose-induced increase in the percentage of S-phase cells[1]. |
| Alias | DAPH-7 |
| Molecular Weight | 365.33 |
| Formula | C20H13F2N3O2 |
| Cas No. | 145915-60-2 |
Storage & Solubility Information
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
| Solubility Information | Ethanol: < 7.31 mg/mL DMSO: 50 mg/mL (136.86 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . A total of 10 animals were administered, and the formula you used is 5% 
DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.Preparation method for in vivo formula: Take 50 μL DMSO main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarify
main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarifyFor Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: buy CGP 53353 | purchase CGP 53353 | CGP 53353 cost | order CGP 53353 | CGP 53353 chemical structure | CGP 53353 in vitro | CGP 53353 formula | CGP 53353 molecular weight
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.